You are here: Industry Insights > Japanese

News List

Sosei Heptares’ COVID-19 programme advances promising molecules pharmatimes
November 23, 2020
Japanese pharma company Sosei Heptares has identified and advanced the ‘most promising’ molecules in its COVID-19 research and development programme.
Lupin to sell Japanese injectable biz to Neopharma group biospectrumasia
August 22, 2019
The transaction is subject to customary closing conditions and has been approved by the Board of Directors of Lupin
Japanese scientists develop 3D printed prosthetic hand biospectrumasia
August 18, 2019
The team is planning on creating a training plan in order to make the best use of the hand
Recommendations Developed for Japanese Encephalitis Vaccine drugs
July 22, 2019
In the issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report...
Japanese researchers use AI to design novel endoscopy biospectrumasia
July 15, 2019
Researchers at Okayama University have developed an early gastric cancer endoscopic diagnosis system using artificial intelligence (AI). The details were presented at the Congress of the Japan Gastroenterological Endoscopy Society (JGES), May 31 – June 2,
Japanese scientists reveal potential of technology to detect cancer biospectrumasia
April 29, 2019
The scientists present a technique that makes use of the binding properties of aptamers, synthetic organic molecules acting as probes for cancer cells.
Daiichi Sankyo receives Japanese marketing approval for two drugs pharmaceutical-technology
January 10, 2019
Daiichi Sankyo has obtained marketing approval in Japan for its minnebro and tarlige tablets to treat hypertension and peripheral neuropathic pain (PNP) respectively.
Mundipharma applies for marketing Remimazolam in Japan biospectrumasia
December 24, 2018
Mundipharma has submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency to market Remimazolam for general anesthesia in Japan.
Takeda shareholders approve $62bn Shire acquisition pharmafile
December 07, 2018
Japanese firm Takeda have gained shareholders’ approval for the $62 billion acquisition of the Irish headquartered company Shire Plc.
AstraZeneca chalks up double Japanese approval in lung and breast cancer pharmafile
July 06, 2018
First up, Imfinzi (durvalumab) has been authorised as maintenance therapy after definitive chemoradiation therapy (CRT) for the treatment of locally-advanced

Previous page 1 2 Next page